Literature DB >> 10882401

Effect of acute nicotine administration on striatal dopamine output and metabolism in rats kept at different ambient temperatures.

T Seppä1, M Ruotsalainen, I Laakso, R Tuominen, L Ahtee.   

Abstract

1. The effect of ambient temperature on the nicotine-induced (0.3, 0.5 or 0.8 mg kg(-1) s.c.) changes of the striatal concentrations of dopamine (DA) and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) was studied in freely-moving rats by in vivo microdialysis. 2. At the ambient temperature of 30 - 33 degrees C, but not at 20 - 23 degrees C, nicotine doses of 0.5 (P<0. 01) and 0.8 mg kg(-1) (P<0.05) significantly increased the extracellular DA concentration. The nicotine doses of 0.5 and 0.8 mg kg(-1) increased the DA metabolite levels similarly at both ambient temperatures studied (P</=0.0001), but the dose of 0.3 mg kg(-1) only at 30 - 33 degrees C (DOPAC: P<0.05; HVA: P<0.01). 3. At 30 - 33 degrees C, dihydro-beta-erythroidine (DHbetaE 2.8 mg kg(-1) i.p.) blocked the nicotine-induced (0.5 or 0.8 mg kg(-1)) increases of extracellular DA concentration but only tended to antagonize the increases of DA metabolites. Mecamylamine (5.0 mg kg(-1) i.p.) blocked the increase of DA output induced by 0.5 mg kg(-1) but not that induced by 0.8 mg kg(-1) of nicotine and fully prevented the nicotine-induced elevations of DOPAC and HVA. 4. Elevation of ambient temperature did not affect the cerebral concentration of nicotine or the nicotine-induced elevation of serum corticosteroids. Also, the rectal temperatures of rats given nicotine at either ambient temperature did not significantly change. 5. Our results show that the nicotine-induced output of striatal DA is enhanced at high ambient temperature. Further, our findings suggest that the nicotinic cholinoceptors mediating the effects of nicotine on striatal DA release are different from those mediating nicotine's effects on DA metabolism.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882401      PMCID: PMC1572162          DOI: 10.1038/sj.bjp.0703402

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

1.  Long-lasting inactivation of nicotinic receptor function in vitro by treatment with high concentrations of nicotine.

Authors:  P P Rowell; D S Duggan
Journal:  Neuropharmacology       Date:  1998       Impact factor: 5.250

Review 2.  The pharmacology of (-)-nicotine and novel cholinergic channel modulators.

Authors:  J D Brioni; M W Decker; J P Sullivan; S P Arneric
Journal:  Adv Pharmacol       Date:  1997

3.  Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats.

Authors:  A Imperato; A Mulas; G Di Chiara
Journal:  Eur J Pharmacol       Date:  1986-12-16       Impact factor: 4.432

Review 4.  Parkinson's disease perspectives on epidemiology and pathogenesis.

Authors:  I I Kessler
Journal:  Prev Med       Date:  1973-03       Impact factor: 4.018

Review 5.  Cigarette smoking and Parkinson's disease.

Authors:  J A Baron
Journal:  Neurology       Date:  1986-11       Impact factor: 9.910

6.  Tetrodotoxin-sensitivity of nicotine-evoked dopamine release from rat striatum.

Authors:  D Marshall; L Soliakov; P Redfern; S Wonnacott
Journal:  Neuropharmacology       Date:  1996       Impact factor: 5.250

7.  Acute administration of nicotine increases the in vivo extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid and ascorbic acid preferentially in the nucleus accumbens of the rat: comparison with caudate-putamen.

Authors:  M P Brazell; S N Mitchell; M H Joseph; J A Gray
Journal:  Neuropharmacology       Date:  1990-12       Impact factor: 5.250

8.  Intrastriatal taurine increases striatal extracellular dopamine in a tetrodotoxin-sensitive manner in rats.

Authors:  M Ruotsalainen; L Ahtee
Journal:  Neurosci Lett       Date:  1996-07-19       Impact factor: 3.046

9.  Different changes in striatal dopamine metabolism induced by nicotine in mice kept at different ambient temperatures. Evidence for partly separate metabolic routes of dopamine derived from separate compartmentations.

Authors:  H Haikala
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-12       Impact factor: 3.000

10.  Induction but not expression of behavioural sensitization to nicotine in the rat is dependent on glucocorticoids.

Authors:  D H Johnson; A I Svensson; J A Engel; B Söderpalm
Journal:  Eur J Pharmacol       Date:  1995-03-24       Impact factor: 4.432

View more
  5 in total

1.  The effect of nicotine in combination with various dopaminergic drugs on nigrostriatal dopamine in rats.

Authors:  Sanna Janhunen; Paula Mielikäinen; Päivi Paldánius; Raimo K Tuominen; Liisa Ahtee; Seppo Kaakkola
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-07-13       Impact factor: 3.000

2.  Nicotinic acetylcholine receptors in the ventral tegmental area mediate the dopamine activating and reinforcing properties of ethanol cues.

Authors:  Elin Löf; Peter Olausson; Andrea deBejczy; Rosita Stomberg; J Michael McIntosh; Jane R Taylor; Bo Söderpalm
Journal:  Psychopharmacology (Berl)       Date:  2007-08-17       Impact factor: 4.530

3.  α3β4 nicotinic acetylcholine receptors in the medial habenula modulate the mesolimbic dopaminergic response to acute nicotine in vivo.

Authors:  Sarah E McCallum; Matthew A Cowe; Samuel W Lewis; Stanley D Glick
Journal:  Neuropharmacology       Date:  2012-04-26       Impact factor: 5.250

4.  Dopaminergic signaling mediates the motivational response underlying the opponent process to chronic but not acute nicotine.

Authors:  Taryn E Grieder; Laurie H Sellings; Hector Vargas-Perez; Ryan Ting-A-Kee; Eric C Siu; Rachel F Tyndale; Derek van der Kooy
Journal:  Neuropsychopharmacology       Date:  2009-12-23       Impact factor: 7.853

5.  Performance of motor associated behavioural tests following chronic nicotine administration.

Authors:  Omamuyovwi M Ijomone; Olayemi K Olaibi; Ifechukwude J Biose; Christian Mba; Kenneth E Umoren; Polycarp U Nwoha
Journal:  Ann Neurosci       Date:  2014-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.